Novartis: 757 jobs cut

Closed sites in Germany and Boston. Investing heavily in AI for drug discovery (BioAIM program) while reducing headcount. The connection to AI is moderate — while the company is investing in AI capabilities, the layoffs were attributed to broader restructuring alongside technology adoption. Of the 757 total positions affected, our methodology estimates that approximately 303 roles (40%) are attributable to AI-driven changes. This is part of a broader pattern in Pharmaceutical where companies are restructuring operations around AI capabilities while reducing headcount in functions susceptible to automation.